Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Altum Pharmaceuticals, a subsidiary of BetterLife Pharma (BETR), is working with Pontificia Universidad Católica de Chile to develop a treatment for COVID-19
  • The treatment, AP-003, is a non-invasive inhaled substance that is administered as a mist to early-stage COVID-19 patients
  • BetterLife Pharma, a biotechnology company, engages in the development and commercialization of psychedelic products
  • BetterLife Pharma Inc. (BETR) is up 1.45 per cent, trading at $0.35 per share

Altum Pharmaceuticals, a subsidiary of BetterLife Pharma (BETR), is working with Pontificia Universidad Católica de Chile to develop a treatment for COVID-19.

Researchers from Altum and Pontificia Universidad Católica de Chile have obtained approval to begin a randomized placebo-controlled trial of BetterLife’s proprietary AP-003 treatment in COVID-19 patients.

AP-003 is a non-invasive inhaled substance that is administered with a nebulizer—which turns medication into a mist that can be inhaled—twice daily for ten days.

Dr. Ahmad Doroudian, CEO of BetterLife, commented on the start of the trials.

“We are excited to initiate this trial of AP-003 in COVID-19 patients in collaboration with the Escuela de Medicina (school of medicine) at Pontificia Universidad Católica de Chile,” he said.

Dr. Arturo Borzutzky, principal investigator of the IN2COVID trial, also commented on the work that is being done.

“There are several reasons why there is a need for an effective, easy to administer, non-invasive treatment, such as AP-003, for COVID-19,” he remarked.

“These reasons include: the time it will take to vaccinate the whole population; not knowing the duration of protection afforded by the current vaccines; emergence of SARS-CoV-2 variants; and emergence of possible totally new coronavirus pandemics in the future.”

BetterLife Pharma, a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders.

BetterLife Pharma Inc. (BETR) is up 1.45 per cent, trading at $0.35 per share as of 9:38 am ET.

More From The Market Herald
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) relaunches AKYNZEO in Brazil

Knight Therapeutics’ (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil.

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel